Blood cancers

News in brief: Trials offer access to novel therapies for AML and MDS; Guidelines recommend NIPT for fetal RHD; Clinico-pathological spectrum of VITT may be wider than we think

Australian trials offer access to precision therapies for AML and MDS Australian AML and MDS patients with excess blasts-2 (MDS-EB2) could access novel therapies years ahead of their expected market availability through two international clinical trials. The HO156/AMLM24 trial will investigate whether midostaurin or gilteritinib can improve survival of newly-diagnosed AML and MDS-EB2 patients with ...

Already a member?

Login to keep reading.

© 2021 the limbic